FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Leukemia topics
Myelogenous
Myelogenous Leukemia
Proliferative
Autoimmune
Stem Cells
Breast Cancer
Rheumatoid Arthritis
Myeloid Leukemia
Acute Myelogenous Leukemia
Lymphocytic
Chronic Lymphocytic Leukemia
Lymphocytic Leukemia
Epigenetic
Multiple Myeloma
Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Leukemia patents



      
           
This page is updated frequently with new Leukemia-related patent applications. Subscribe to the Leukemia RSS feed to automatically get the update: related Leukemia RSS feeds. RSS updates for this page: Leukemia RSS RSS


Date/App# patent app List of recent Leukemia-related patents
02/26/15
20150057188
 Quantitative multiplex methylation-specific pcr patent thumbnailnew patent Quantitative multiplex methylation-specific pcr
Methods are provided for diagnosing in a subject a condition, such as a carcinoma, sarcoma or leukemia, associated with hypermethylation of genes by isolating the genes from tissue containing as few as 50 to 1000 tumor cells. Using quantitative multiplex methylation specific pcr (qm-msp), multiple genes can be quantitatively evaluated from samples usually yielding sufficient dna for analyses of only 1 or 2 genes.
The Johns Hopkins University
02/26/15
20150056608
 Method for treating infectious diseases using emissive energy patent thumbnailnew patent Method for treating infectious diseases using emissive energy
The present invention relates to the treatment of infectious diseases, specifically by extracorporeally eradicating the pathogen. This invention comprises methods for the extracorporeal treatment of infectious diseases that will remove infectious pathogens (leukemia cells, bacteria, viruses, or fungi causing a septicemia, metastatic cancer cells, target protein, viruses, parasites, fungi and prions) in humans by targeting such pathogens with a laser or other high-energy source of emissive radiation.
Marv Enterprises, Llc
02/26/15
20150056171
 Methods of predicting clinical outcome of chronic lymphocytic leukemia patent thumbnailnew patent Methods of predicting clinical outcome of chronic lymphocytic leukemia
Provided are methods of predicting the outcome of a chronic lymphocytic leukemia (cll) in a subject. The methods comprise performing a polymerase chain reaction assay for an igh locus on a nucleic acid from a biological sample from a subject with cll, wherein the pcr assay amplifies a non-coding region of the igh locus, sequencing a product from the pcr assay, and determining a level of mutation in the non-coding region of the igh locus.
University Of Rochester
02/19/15
20150051277
 Compounds from anisomeles heyneana patent thumbnailCompounds from anisomeles heyneana
The present invention describes use of compounds of formula 1 or 2 or their compositions for the treatment of leukemia and use of compound of formula 1 or its composition for treatment of infections caused due to m. Tuberculosis.
Council Of Scientific & Industrial Research
02/19/15
20150051236
 Combinations useful for the treatment of chronic lymphocytic leukemia patent thumbnailCombinations useful for the treatment of chronic lymphocytic leukemia
The invention relates to a combination which comprises (a) a dna damaging agent; and (b) 4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidioyl]amino]-n-[5-(4-methyl-1h-imidazol-1-yl)-3-(trifluoromethyl)phenyl]benzamide (“nilotinib”); a pharmaceutical composition comprising such a combination and optionally at least one pharmaceutical acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment chronic lymphocytic leukemia (cll); the use of such a combination for the preparation of a medicament for the treatment of cll; a commercial package or product comprising such a combination; and to a method of treatment of a warm-blooded animal, especially a human.. .
Novartis Ag
02/19/15
20150051196
 Inhibitors of c-fms kinase patent thumbnailInhibitors of c-fms kinase
Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
02/19/15
20150051156
 Method of treating leukemia using rice prolamin patent thumbnailMethod of treating leukemia using rice prolamin
The present invention relates to a method of treating leukemia using rice prolamin, comprising administering a daily dose of isolated prolamin to a patient suffering from leukemia for a period of time from 5 days to 10 days. For the treatment application, the rice prolamin can stimulate human peripheral blood mononuclear cell (pbmc) to produce cytokines, such as tumor necrosis factor-alpha, to inhibit growth of and induce differentiation of human leukemia cells.
Mackay Memorial Hospital
02/19/15
20150050274
 Methods and biomarkers for detection and treatment of mature t-cell leukemia patent thumbnailMethods and biomarkers for detection and treatment of mature t-cell leukemia
The present invention relates to methods and biomarkers for detection and characterization of mature t-cell neoplasias/leukemias (e.g., t-cell prolymphocytic leukemia, sezary syndrome) in biological samples (e.g., tissue samples, blood samples, plasma samples, cell samples, serum samples).. .
The Regents Of The University Of Michigan
02/12/15
20150045361
 Heterocyclic compounds and their uses patent thumbnailHeterocyclic compounds and their uses
Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (sle), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, the present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as acute myeloid leukaemia (aml) myelo-dysplastic syndrome (mds) myelo-proliferative diseases (mpd) chronic myeloid leukemia (cml) t-cell acute lymphoblastic leukaemia (t-all) b-cell acute lymphoblastic leukaemia (b-all) non hodgkins lymphoma (nhl) b-cell lymphoma and solid tumors, such as breast cancer.. .
Amgen Inc.
02/12/15
20150045339
 Nitrogen-containing heterocyclic compound or salt thereof patent thumbnailNitrogen-containing heterocyclic compound or salt thereof
The object is to provide an fms-like tyrosine kinase 3 (flt3) inhibitor useful as a therapeutic agent for acute myeloid leukemia (aml). A novel nitrogen-containing heterocyclic compound represented by the general formula [1] or a salt thereof is provided.
Fujifilm Corporation
02/12/15
20150044237

Chimeric molecule involving oligomerized fasl extracellular domain


New chimeric molecules involving in their structure, a combination of the extracellular domain (ec) of the fasl protein and a domain enabling oligomerisation of this fas ligand (fasl) ec domain, such as the ig-like (so-called ig in the following pages) domain of the gp190 receptor for the leukemia inhibitory factor (lif), or involving in their structure variants of the domains. Also, compositions including the chimeric molecule defined herein and the use of these chimeric molecules especially to trigger cytotoxic activity toward cells sensitive to fasl..
Centre National De La Recherche Scientifique
02/05/15
20150038481

Pyrimidine compounds for the treatment of cancer


Described are compounds of formula i or formula ii: wherein: ring a is a 5- or 6-membered heteroaryl group; dashed lines are optional double bonds; x is n or o; y is a carbon atom or an s or n heteroatom in ring a in any suitable location; and substituents are as given herein. Compositions containing the same and methods of using the same in treating cancers such as acute lymphoblastic leukemia are also described..
The University Of North Carolina At Chapel Hill
02/05/15
20150038450

Combination therapy for the treatment of cancer


Described are methods and compositions for treating cancer that include a dopamine receptor (dr) antagonist such as thioridazine and a chemotherapeutic agent. Optionally, the chemotherapeutic agent is a dna synthesis inhibitor such as cytarabine or a microtubule inhibitor such as paclitaxel or docetaxel.
Mcmaster University
02/05/15
20150038360

Method for multiplex-detecting chronic myelogenous leukemia gene using cleavable probe


One embodiment of the present invention provides a detection kit for detecting a chronic myelogenous leukemia (cml) gene expression, wherein the detection kit includes a primer set which is specifically bound to the cml gene; and a cleavable probe which is specifically bound to the inside of a cml gene amplification product which is amplified by the primer set. Another embodiment of the present invention provides a method of measuring the cml gene expression by using the detection kit according to one embodiment of the present invention.
Samsung Life Public Welfare Foundation
02/05/15
20150037283

Combination therapy with anti-cd74 antibodies provides enhanced toxicity to malignancies, autoimmune disease and other diseases


Disclosed are compositions and methods comprising combinations of anti-cd74 antibodies with a therapeutic agent that is attached to the anti-cd74 antibody or separately administered. Preferably, the therapeutic agent is an antibody that binds to an antigen different from cd74, such as cd19, cd20, cd21, cd22, cd23, cd37, cd40, cd40l, cd52, cd80, il-6, cxcr4 or hla-dr.
Ibc Pharmaceuticals, Inc.
01/29/15
20150031643

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome ii


The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with azacitidine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. .
Boehringer Ingelheim International Gmbh
01/29/15
20150031642

Combination treatment of acute myeloid leukemia and myelodysplastic syndrome i


The present invention relates to the use of volasertib or a salt thereof or the hydrate thereof in combination with decitabine or a salt thereof or the hydrate thereof for treating patients suffering from acute myeloid leukemia (aml) or myelodysplastic syndrome (mds).. .
Boehringer Ingelheim International Gmbh
01/29/15
20150031641

Methods and compositions for the diagnosis, prognosis and treatment of acute myeloid leukemia


Gene mutations are associated with the progression of acute myeloid leukemia (aml). The invention relates to methods and systems for evaluating the progression of aml based on these gene mutations.
Memorial Sloan-kettering Cancer Center
01/29/15
20150030623

Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene


The present invention provides vectors that contain and express in vivo or in vitro felv antigens that elicit an immune response in animal or human against felv, compositions comprising said vectors and/or felv polypeptides, methods of vaccination against felv, and kits for use with such methods and compositions.. .
Universite Paris-sud
01/29/15
20150030533

Compositions and methods for the detection diagnosis and therapy of hematological malignancies


Disclosed are methods and compositions for the detection, diagnosis, prognosis, and therapy of hematological malignancies, and in particular, b cell leukemias, lymphomas and multiple myelomas. Disclosed are compositions, methods and kits for eliciting immune and t cell responses to specific malignancy-related antigenic polypeptides and antigenic polypeptide fragments thereof in an animal.
Corixa Corporation
01/22/15
20150025232

Heptamer-type small guide nucleic acids inducing apoptosis of human leukemia cells


There is provided a heptamer-type small guide nucleic acid that comprises any of the 7-base sequences of seq id nos: 1 to 15, and induces apoptosis of human leukemia cells. A leukemia therapeutic agent containing the heptamer-type small guide nucleic acid as an active ingredient is also provided.
01/22/15
20150025135

Methods and compositions for treating leukemia


The present invention provides methods and compositions for treating leukemia by cyclohexenone compounds.. .
Golden Biotechnology Corporation
01/22/15
20150023964

Fcgammariib-specific antibodies and methods of use thereof


The present invention relates to antibodies or fragments thereof that specifically bind fcγriib, particularly human fcγriib, with greater affinity than the antibodies or fragments thereof bind fcγriia, particularly human fcγriia. The present invention also provides the use of an anti-fcγriib antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a b-cell malignancy, particularly, b-cell chronic lymphocytic leukemia or non-hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an ige-mediated allergic disorder, or one or more symptoms thereof.
Macrogenics, Inc.
01/22/15
20150023870

Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases


Disclosed herein are compositions and methods of use comprising hexavalent dnl complexes. Preferably, the complexes comprise anti-cd20 and/or anti-cd22 antibodies or fragments thereof.
Ibc Pharmaceuticals, Inc.
01/15/15
20150018355

Compounds and methods for treating leukemia


Compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating leukemia. In particular, compounds, and methods and uses of compounds, and pharmaceutical compositions thereof, are described herein for treating acute lymphoblastic leukemia (all) in its various forms..
Indiana University Research And Technology Corporation
01/08/15
20150011628

Substitute diphenylamine compounds use thereof as antitumor agents


The compound represented by formula (i) showed potent antitumor activity, especially to cure or alleviate the cancer causing by cancer cells of human tissue or organ. The preferred cancers are: colon cancer, liver cancer, lymph cancer, lung cancer, esophageal cancer, breast cancer, central nervous system cancer, melanoma, ovarian cancer, cervical cancer, renal cancer, leukemia, prostatic cancer, pancreatic cancer, bladder cancer, rectal cancer, osteosarcoma, nasopharynx cancer or stomach cancer..
01/08/15
20150011618

Synthesis of polyhydroxy chromenone compounds and their anti-tumor effects


The present invention is directed to chromenone compounds of formula (i), pharmaceutically acceptable salts, prodrugs thereof, and the composition comprising the compounds or the like. They can be used to modulating the function of estrogen receptor er-α36 preventing and/or treating the estrogen related diseases, such as breast cancer, leukemia, liver cancer and etc..
Beijing Shenogen Pharma Group Ltd.
01/08/15
20150010475

Crlf-2 binding peptides, protocells and viral-like particles useful in the treatment of cancer, including acute lymphoblastic leukemia (all)


The present invention relates to the use of which are attached or anchored phospholipid biolayers further modified by crlf-2 and cd 19 binding peptides which may be used for delivering pharmaceutical cargos, to cells expressing crlf-2 and cd 19, thereby treating cancer, in particular, acute lymphoblastic leukemia (all), including (b-precursor acute lymphoblastic leukemia (b-all). Novel crlf-2 binding peptides and clrf-2 and cd19-binding viral-like particles (vlps) useful in the treatment of cancer, including all are also provided..
Sanda Corporation
01/01/15
20150005361

Induced pluripotent stem cell model of chronic myeloid leukemia revealed olfactomedin 4 as a novel therapeutic target in leukemia stem cells


Disclosed herein are compositions and methods to treat and reduce therapeutic resistance in chronic myelogenous leukemia. Also disclosed herein are methods to generate leukemia stem cell like cells (ilscs) generated from cml patient-derived ipscs, and methods for utilizing ilscs in screens to identify modulators of cml drug resistance and gene targets that underlie cml drug resistance..
Wisconsin Alumni Research Foundation
12/25/14
20140378457

Inhibitors of c-fms kinase


Wherein z, x, j, r2 and w are set forth in the specification, as well as solvates, hydrates, tautomers and pharmaceutically acceptable salts thereof, that inhibit protein tyrosine kinases, especially c-fms kinase. Methods of treating autoimmune diseases; and diseases with an inflammatory component; treating metastasis from ovarian cancer, uterine cancer, breast cancer, prostate cancer, lung cancer, colon cancer, stomach cancer, hairy cell leukemia; and treating pain, including skeletal pain caused by tumor metastasis or osteoarthritis, or visceral, inflammatory, and neurogenic pain; as well as osteoporosis, paget's disease, and other diseases in which bone resorption mediates morbidity including rheumatoid arthritis, and other forms of inflammatory arthritis, osteoarthritis, prosthesis failure, osteolytic sarcoma, myeloma, and tumor metastasis to bone with the compounds of formula i, are also provided..
12/25/14
20140377220

Gene expression signatures for staging and prognosis of prostate, breast and leukemia cancers


The present invention is drawn to methods of assessing and treating cancers such as erg-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (hstg3); lymphoid enhancer-binding protein factor 1 (lef1); frizzled-related protein (frzb); annexin a4 (anxa4); meis homeobox 2 (meis2); syndecan binding protein (syntenin) (sdcbp); ankyrin 3, node of ranvier (ankyrin g) (ank3); chromodomain helicase dna binding protein 5 (chd5); phospholipase a2, group vii (platelet-activating factor acetylhydrolase, plasma) (pla2g7); and wingless-type mmtv integration site family member 2 (wnt2)..
Uti Limited Partnership
12/18/14
20140371306

Pharmaceutical compositions comprising lignans and their derivatives for treating hyperplastic diseases


The present invention relates to a pharmaceutical composition comprising specific compounds which may be obtained from leontopodium alpinum cass. (edelweiss).
UniversitÄt Innsbruck
12/18/14
20140371239

Menin-mll inhibitors and methods of use thereof


The present invention relates generally to compounds that inhibit the binding of menin and mll or mll fusion proteins and methods of use thereof. In particular embodiments, the present invention provides compositions comprising piperidine-containing compounds and methods of use thereof to inhibit the interaction of menin with mll oncoproteins (e.g., mll1, mll2, mll-fusion oncoproteins), for example, for the treatment of leukemia, solid cancers, diabetes, and other diseases dependent on activity of mll1, mll2, mll fusion proteins, mll-ptd and/or menin..
Vanderbilt University
12/18/14
20140370039

Il-12 immunotherapy for cancer


Compositions and methods for delivering immune modulatory molecules to result in a therapeutic effect are disclosed. The compositions and methods use stably integrating lentiviral delivery systems.
University Health Network
12/18/14
20140370023

Erg monoclonal antibodies


Monoclonal antibodies, or antigen-binding fragments thereof, that bind to erg, and more specifically, to an epitope formed by amino acids 42-66 of erg3 are disclosed. The monoclonal antibodies can be non-human antibodies (e.g., rabbit or mouse) or humanized monoclonal antibodies having the cdr regions derived from those non-human antibodies.
The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.
12/18/14
20140370010

Treatment of leukemias and chronic myeloproliferative diseases with antibodies to epha3


The invention provides methods and compositions comprising anti-epha3 antibodies for the treatment of myeloproliferative disorders.. .
Kalobios Pharmaceuticals, Inc.


Popular terms: [SEARCH]

Leukemia topics: Myelogenous, Myelogenous Leukemia, Proliferative, Autoimmune, Stem Cells, Breast Cancer, Rheumatoid Arthritis, Myeloid Leukemia, Acute Myelogenous Leukemia, Lymphocytic, Chronic Lymphocytic Leukemia, Lymphocytic Leukemia, Epigenetic, Multiple Myeloma, Polyphenol

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Leukemia for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Leukemia with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         









0.6685

3707

74 - 0 - 73